Vaidya Sane
Vaidya Sane Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
5 of 5 strong
The short version
FY '26 expected revenue: INR 115-120 crores. FY '26 revenue expected at INR 115-120 crores, with 20% growth and EBITDA margins around 17-18%.
From Vaidya Sane's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- FY '26 expected revenue: INR 115-120 crores.
- FY '27 projected sales: Around INR 180 crores; INR 50-55 crores from hospitals, INR 125-135 crores from clinics, with potential to surpass this figure.
- FY '28 sales target: INR 280 crores planned, with aim to surpass and possibly reach INR 320-350 crores.
- EBITDA margins expected to increase to 30%-35% by FY '28 if INR 280 crore turnover is achieved.
- Revenue growth drivers include increased patient footfall in clinics, expansion of hospital bed capacity from current 110 beds to 350+ beds by FY '28.
- Scale-up of Madhavprash sales from 15,000-20,000 units/month currently to target of 1 lakh units/month in next 24 months.
2 more points from Vaidya Sane's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Vaidya Sane said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current/future CAPEX plans:
- Expansion of hospitals at Khopoli (100 extra beds) and Nagpur (80 beds) with an estimated investment of INR 25-30 crores.
- Vadodara hospital expansion on a rental model; no construction CAPEX expected but installation costs applicable.
- Ongoing construction started for Khopoli hospital expansion; Nagpur hospital CAPEX to commence in 3-4 months.
- Capacity expansion at Nagpur hospital adding 5 beds, investment approx. INR 55 lakhs.
- Launch of Urja Neuro Care facility focused on integrative neuro treatments, estimated cost about INR 1.8 crores.
- Plans to increase bed capacity to around 350-370 beds in next 12-15 months.
- Aim to have about 1000 beds nationwide in 2-3 years.
- Strategic investments:
- International expansion via collaboration with Maxura Healthcare in Malaysia to establish an Ayurvedic therapy center.
2 more points from Vaidya Sane's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vaidya Sane said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Vaidya Sane's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Vaidya Sane's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Aprameya Enginee (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
- Earkart (Q2 FY26)
Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). Key concall takeaways from…
- QMS Medical Allied Services Ltd (Q2 FY26)
The only related transaction noted is the recent acquisition of Saarathi increasing stake from 51% to 76%, but no fundraising details were shared with respect…
- Poly Medicure Ltd (Q2 FY26)
1,090 crores, representing over 25% growth compared to H1 (Rs. Key concall takeaways from Poly Medicure's Q2 FY26 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Vaidya Sane and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vaidya Sane Q2 FY26 results?
FY '26 expected revenue: INR 115-120 crores. FY '26 revenue expected at INR 115-120 crores, with 20% growth and EBITDA margins around 17-18%.
What is Vaidya Sane share price analysis?
Vaidya Sane currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 19.9 with a market cap of ₹179 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vaidya Sane planning capital expenditure?
Current/future CAPEX plans: - Expansion of hospitals at Khopoli (100 extra beds) and Nagpur (80 beds) with an estimated investment of INR 25-30 crores. - Vadodara hospital expansion on a rental model; no construction CAPEX expected but installation costs applicable. - Ongoing construction started for Khopoli hospital expansion; Nagpur hospital CAPEX to commence in 3-4 months. - Capacity expansion at Nagpur hospital adding 5 beds, investment approx.
Keep Vaidya Sane on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.